PRAC

(redirected from Pharmacovigilance Risk Assessment Committee)
Category filter:
AcronymDefinition
PRACPractice
PRACPharmacovigilance Risk Assessment Committee (European Medicines Agency)
PRACParks and Recreation Advisory Committee
PRACPascagoula River Audubon Center (Moss Point, MS)
PRACProject Rental Assistance Contract
PRACPacific Rim Advisory Council
PRACPetroleum Research Atlantic Canada
PRACPublic Relations Advisory Committee
PRACProgram Review and Assessment Committee
PRACPlanning and Resource Allocation Committee
PRACPeer Review Advisory Committee
PRACProfessional Relations Advisory Committee
PRACPuerto Rican Action Committee (Woodbine, NJ)
PRACParks and Recreation Advisory Commission
PRACPlymouth Rock Assurance Corporation (Boston, MA)
PRACPlaced Remedial Action Contract
PRACProgram Resource Advisory Committee
PRACPre-Placed Remedial Action Contract
PRACPrison Reform Advocacy Center
PRACProved Reserve Acquisition Costs
PRACProject Review and Advisory Committee
PRACPocono Regional Aquatic Club (Pennsylvania)
PRACPlanning and Resource Advisory Council
PRACPractice and Research: Advancing Collaboration
PRACPark Rangers Association of California
PRACParks and Recreation Advisory Council
PRACPrograms Risk Advisory Committee
PRACParachute Regiment Aptitude Course (UK)
PRACPotomac River Angler's Club (fishing)
PRACProblem-Related Accounts Corrections
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
The Registry also fulfils a post-marketing commitment to the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency.
18, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) issued a statement concluding that "Esmya may have contributed to the development of some cases of serious liver injury." (16) PRAC also issued a number of precautionary recommendations intended to protect patients from liver injury, including a warning to patients with liver problems not to use Esmya, and the implementation of regular checks on the liver health of patients currently taking the drug.
Several years ago, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee reviewed randomized controlled trials of strontium ranelate and concluded that it increases the risk of cardiovascular disease.
The EMA's Pharmacovigilance Risk Assessment Committee will undertake the initial review of Zinbryta and come up with a set of recommendations.
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) did not identify any adverse effects of brain retention of gadolinium.
But the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency says physicians should use caution when prescribing high-dose ibuprofen.
Deliberations of the Pharmacovigilance Risk Assessment Committee and the FDA's on-going evaluation of unconfirmed safety signals are posted on the internet.
This decision was taken for the Pharmacovigilance Risk Assessment Committee in July 2012, the Paediatric Committee in September 2012, the Committee for Orphan Medicinal Products in October 2012, the Committee on Herbal Medicinal Products in September 2013 and now for the Committees for Medicinal Products for Human Use and for Medicinal Products for Veterinarian Use.
One of the most significant July 2012 updates pertains to the Pharmacovigilance Risk Assessment Committee. The job of this department is to “detect, assess, understand and prevent adverse reactions, and to identify and take actions to reduce the risks of and increase the benefits from, medicinal products for human use.”1 To do so, the Pharmacovigilance Risk Assessment Committee “may at any time ask the marketing authorization holder to forward data demonstrating the risk-benefit balance remains favorable.”2 This means that in addition to submitting the Periodic Safety Update Reports (PSURS), which contain cumulative data about the drug's safety throughout its lifecycle, drug safety departments will also need to produce organized risk-benefit evaluations.
The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency reviewed randomized controlled trials of strontium ranelate and concluded that there is an increased risk of cardiovascular disease in patients treated with this compound.
The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) will give a recommendation on the Diane 35 pill mid-May, and another in July on other hormonal contraceptives authorised at EU level.
Full browser ?